AI assistant
Terns Pharmaceuticals, Inc. — Director's Dealing 2021
Feb 4, 2021
32559_dirs_2021-02-04_d326d090-2d25-477a-9516-4581252cc742.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2021-02-04
Reporting Person: Yoon Seokho Bryan (See Remarks)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $9.24 | 2030-12-29 | Common Stock (265775) | Direct |
Footnotes
F1: This option is early exercisable. 25% of the shares subject to the option vest on the first anniversary measured from November 6, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.
F2: Reflects a 1-for-14 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.